20 1 1 On April 20th, the Group was listed on the main board of the Hong Kong Stock Exchange (stock code: 0101). HK)。 Headquartered in Hong Kong, the Group has established an investment and marketing management headquarters in Shanghai, a research and development company in Beijing, and dozens of R&D, pharmaceutical and sales enterprises in Hong Kong, Shanghai, Jiangsu, Beijing, Guangzhou, Changsha and Hainan.
The Group focuses on the development of its own brand core products, covering many therapeutic fields such as tumor and blood system diseases, digestive system diseases, central nervous system diseases and respiratory system diseases. * * There is a product registration number of 13 1 approved by China Food and Drug Administration, among which more than 20 products are being produced and sold by pharmaceutical enterprises under the Group.
Welcome to the company website:
Legal Representative: Wu Tie.
Date of establishment: 20 12- 10-26.
Registered capital: USD 30 million.
Location: Shanghai.
Unified social credit code: 9131000054589076l
Business status: surviving (in business, in business, on record)
Industry: leasing and business services
Company type: limited liability company (wholly owned by Taiwan, Hong Kong and Macao)
English name: Tailing (China) Investment Co., Ltd.
Number of employees: 100-499.
Address: Room 208, Floor 2, Building 2, No.2250 Pudong South Road, China (Shanghai) Pilot Free Trade Zone.
Scope of business: (1) investing in areas where foreign investment is allowed by the state according to law; (2) According to the written entrustment of the invested enterprise (unanimously approved by the board of directors), provide the following services to the invested enterprise: 1. Assist or act as an agent for the invested enterprise to purchase machinery and equipment, office equipment, raw materials and spare parts needed for production from home and abroad, sell the products produced by the invested enterprise at home and abroad, and provide after-sales service; (2) Balancing the foreign exchange of the invested enterprise with the consent and supervision of the foreign exchange administration department; 3. Provide the invested enterprise with technical support, staff training, internal personnel management and other services in the process of product production, sales and market development; 4. Assist the invested enterprises to seek loans and provide guarantees; (three) to set up research and development centers or departments in China to engage in research and development of new products and high technologies, transfer research and development results, and provide corresponding technical services; (four) to provide consulting services for the parent company, and to provide consulting services such as market information and investment policies related to its investment for its affiliated companies; (five) to undertake the service outsourcing business of the parent company and affiliated companies.
Projects that must be approved according to law can only carry out business activities after being approved by the relevant departments.